SCHEMBL16235309

SCHEMBL16235309

COc1cnc(Cl)nc1NS(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR4 P51679 4/20 0.58
▸ S100A9 P06702 3/20 0.50
▸ ACLY P53396 2/20 0.46
▸ PSEN1 P49768 2/20 0.45
▸ PSEN2 P49810 2/20 0.45
▸ APH1B Q8WW43 2/20 0.45
▸ NCSTN Q92542 2/20 0.45
▸ APH1A Q96BI3 2/20 0.45
▸ PSENEN Q9NZ42 2/20 0.45
▸ HTT P42858 1/20 0.43
▸ HTR6 P50406 1/20 0.42
▸ TP53 P04637 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ EDNRB P24530 1/20 0.40
▸ EDNRA P25101 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP3A4 P08684 3/20 0.39
▸ CYP2D6 P10635 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235285 0.83 CCR4 (0.61) CCR4PSEN1PSEN2APH1BNCSTN
SCHEMBL16235384 0.81 S100A9 (0.67) CCR4S100A9ALDH1A1KDM4ESMN1; SMN2
SCHEMBL16235306 0.80 S100A9 (0.67) CCR4S100A9ACLYPSEN1PSEN2
SCHEMBL16235299 0.78 CCR4 (0.47) CCR4S100A9ACLYPSEN1PSEN2
SCHEMBL5957166 0.74 CCR4 (0.64) CCR4
SCHEMBL16235473 0.74 ACLY (0.53) CCR4S100A9ACLYPSEN1PSEN2
SCHEMBL1732669 0.74 CCR4 (1.00) CCR4S100A9EDNRA
SCHEMBL16235831 0.73 CCR4 (0.49) CCR4S100A9ACLYPSEN1PSEN2
SCHEMBL16235497 0.73 CCR4 (0.76) CCR4S100A9
SCHEMBL16235616 0.72 CCR4 (0.51) CCR4S100A9ACLYPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 CCR4 4428/4885S100A9 1/4885ACLY 4724/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 CCR4 4428/4885S100A9 1/4885ACLY 4724/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B CCR4 4504/4885S100A9 1/4885ACLY 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback